In contrast to blockage of VEGF signaling alone by anti-VEGF antibody, FOSL2 knockdown in CAFs combined with VEGF signaling inhibitors could augment the suppressive efficiencies to tumor angiogenesis, indicating that FOSL2 acted as an obviously proangiogenic effector in the VEGF-independent pathway. The gene discussed is VEGFA; the disease is neoplasm.